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Comparison of plasma prolactin and CEA in monitoring patients with
adenocarcinoma of colon and rectum
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S.N. Trivedi & D.B. Balar
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Summary Plasma prolactin (PRL) and carcinoembryonic antigen (CEA) were measured by radioimmunoas-
say in 74 patients with adenocarcinoma of colon and rectum. The markers were correlated with disease stage,
histological grade and progression/remission of disease. The circulating preoperative median PRL and CEA
levels were significantly higher in colorectal cancer patients than in their respective controls. PRL was elevated
in all Dukes stages and in all histological grades of the tumour whereas the rise in CEA was more pronounced
in Dukes D. Out of 74 patients, 29% (21/74) developed recurrent disease and 31% (23/74) responded to the
treatment. With regard to monitoring recurrence(s), the predictive value of PRL was 94% which was
significantly greater than that of CEA which was only 62%. In patients who developed liver metastases PRL
remained elevated whereas CEA showed more than 100-fold increase. Therefore, we feel that CEA is a better
marker for monitoring patients who developed liver metastases. From our results, we suggest that PRL can be
used as a better overall marker for detecting recurrence(s) in patients with colorectal adenocarcinoma.
Recently, we have published data on circulating prolactin
levels in patients with breast cancer (80% of these had
advanced disease i.e. with stage III and IV). The data mainly
concern relationship between circulating prolactin and histo-
logic grade, estrogen- and progesterone-receptor (ER, PR)
and 2 years postoperative survival (Bhatavdekar et al.,
1990a). We have also found plasma prolactin useful both as
an indicator of disease progression and as short-term prog-
nosticator in patients with advanced breast cancer (Bhatav-
dekar et al., 1990b; 1992). In light of the interesting and
convincing results obtained by us in breast cancer patients,
we have now tested the significance of prolactin in colorectal
cancer, another common cancer in this region, by comparing
simultaneously prolactin results with those of CEA.
In this study therefore, we have compared the sensitivity
and specificity of prolactin and CEA and thus the relative
usefulness of these markers in monitoring recurrences in
patients with colorectal adenocarcinomas. In addition,
plasma prolactin and CEA levels were also correlated with
disease stage and histologic grade.
Materials and methods
Patients
Seventy-four colorectal cancer patients treated at The
Gujarat Cancer & Research Institute, Ahmedabad, India
were included in the study between January 1987 to July
1991. There were 46 males, ten premenopausal and 18 post-
menopausal females. Age matched healthy controls of either
sex (n = 50) were also examined. Only those females who had
ceased to menstruate for 5 years were regarded as post-
menopausal.
Blood collection
Blood samples were collected in EDTA, disodium salt coated
tubes (1-2 mg ml-') for prolactin (PRL) and CEA estima-
tions strictly between 9.0 and 11.0 a.m. preoperatively and at
monthly intervals thereafter. The plasma was separated
within 1-2 h of collection, aliquoted and stored at - 70°C.
Assays were carried out within 1 month of collection.
Pathological examination
Disease was staged using Dukes system (Dukes & Bussey,
1958). The histologic grades were assessed independently by
two histopathologists who were unaware of other para-
meters.
Therapy
The primary treatment offered to the patients was surgery
(curative resection-Dukes A to C). Operative findings were
noted of all the patients. Postoperative radiotherapy and/or
chemotherapy was instituted. Patients with Dukes C and D
received chemotherapy (5 FU, n = 47). The treatment was
planned by clinical oncologists of our institute.
Assessment ofdisease activity
The preoperative assessment was done using standard
methods viz. sigmoidoscopy, barium enema, chest X-ray,
abdomino-pelvic ultrasonography and biochemical tests for
liver and renal functions. During follow-up the patients
underwent clinical and biochemical examinations comple-
mented, if necessary, with radiologic, ultrasonographical and
fine needle aspiration cytology.
Seventy-four patients were initially included in the study,
however, at the end of 2 years, 23 patients responded to the
treatment, 21 developed recurrence and rest were lost to
follow-up. In patients who developed recurrence, 1/21 (5%)
each had Dukes B & D whereas 19/21 (90%) had Dukes C
disease. 15/21 (71%) developed local recurrence, 3/21 (14%)
developed liver metastases, 2/21 (10%) developed bone and
1/21 (5%) developed lung metastases.
Plasma PRL and CEA were assayed using double antibody
RIA kits (Diagnostic Products Co., USA). The assays were
performed in duplicate with an intra- and inter-assay coeffic-
ient of variation (CV) of 3-5% and 5-8% respectively. PRL
values > 15.0 ng ml-' for males, >20.0 ng ml-' for pre-
menopausal and > 10.0 ng ml-' for postmenopausal females
were considered for % elevation. CEA levels above 5.0 ng
ml-' was regarded as % elevated.
Criteria for positive tests were: continual rise in the marker
level after an initial fall or persistent high level of the marker
as an indicator of relapse and/or no response to treatment.
Statistical analysis
The statistical significance of differences between various
groups was calculated by Mann-Whitney U-test. a- value
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<0.05 (two tailed test) were considered statistically signi-
ficant. Karl-Pearson correlation coefficient (r) was used to
calculate correlation between two parameters. Sensitivity,
specificity and predictive values were calculated as described
by Tondini et al. (1988).
Results
Preoperative plasma PRL and CEA levels for controls and
colorectal cancer patients are shown in Table I. No correla-
tion was observed bewteen two markers (r = + 0.037).
Median marker levels were significantly elevated in colorectal
carcinoma patients. Table II shows the distribution of
patients according to Dukes stages. Sixty-three percent of our
patients had advanced disease (C and D). Median PRL level
in male patients was higher in Dukes B and C than in D
(Figure 1). Dukes D patients showed higher CEA levels than
A, B and C (Figure 2).
The median levels of PRL and CEA were more or less
similar in all the three grades of the tumour. This may be due
to the fact that 91% patients had histologic grade II and III
tumour.
Markers in responders
All patients who responded to various therapeutic modalities
at the end of 2 years showed decreased PRL and CEA levels.
The difference was statistically significant only for PRL
(Table III). Non-progressive elevation of CEA was seen in
7/23 (30%).
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Figure 1 Distribution of prolactin for controls and Dukes stages
of colorectal cancer patients. (M - males; F - females).
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Figure 2 Distribution of CEA for controls and Dukes stages of
colorectal cancer patients.
Table II Distribution of the patients according to Dukes stage
n Males Premenopausal Postmenopausal
Colorectal
Cancer patients 74 46 10 18
Age range
(years): 74 17-75 25-45 40-84
Dukes
A 02 2 (4%) - -
B 25 16 (35%) 1 (10%) 8 (44%)
C 34 19 (41%) 7 (70%) 8 (44%)
D 13 09 (20%) 2 (20%) 2 (12%)
Table III PRL and CEA in response to disease status
n Prolactin CEA
(median; ngml-') (median; ngml-')
Responders
Pretherapeutic 23 56.50a 09.40
Range 1.47-490.0 0.60-39.70
At the end of 2
years 23 07.76a 05.00
Range 1.00-023.0 0.83-11.00
Non-responders
Pretherapeutic 21 16.00 07.00
Range 7.93-057.30 1.15-78.00
Before relapse 21 13.40b 08.85
Range 2.91-038.00 0.00-154.85
At relapse 21 33.60b 26.06
Range 5.63-105.00 0.00-620.00
a,ba < 0.01
Table I Prolactin and CEA in colorectal carcinoma patients at diagnosis
Prolactin CEA
(median; ngml-') (median; ngml-')
n Males n PR-Ma n po_Mb n
Controls 14 6.20 21 08.50 15 05.80 25 1.80
Range 2.3-009.82 1.0-13.50 0.0-009.0 0.0-4.3
Colorectal
cancer 46 24.50 10 33.75 18 19.80 74 7.00
patients
Range 1.2-195.0 1.0-490.0 1.45-165.0 0.6-130.30
% elevation 67 50 89 76
(above upper
normal limit)
Mann-Whitney <0.01 <0.01 <0.01 <0.01
U-test-x
aPR-M = Premenopausal, bPO_M = postmenopausal.
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Markers in patients who developed recurrence
On sequential follow-up, the PRL levels reduced at response
whereas with the appearance of local/distant metastases, the
PRL levels increased significantly (Table III). It was observed
that the rise in PRL preceded disease progression by approx-
imately 2-3 months. Moreover, PRL levels also remained
elevated through out the course of disease in patients who
did not respond to adjuvant therapy (Figure 3). On sequen-
tial follow-up, CEA levels reduced with remission whereas
with appearance of recurrence, the CEA levels increased only
in 17/21 (81%) patients (Table III). In patients with Dukes
D, as the disease progressed PRL remained elevated but
CEA showed remarkable increase (Figure 4).
Table IV Sensitivity, specificity and predictive value of PRL and
CEA
Prolactin CEA
Sensitivity 94% 76%
Specificity 96% 65%
Predictive value 94% 62%
Sensitivity, specificity andpredictive values ofthe markers
Sensitivity, specificity and predictive values of PRL and CEA
in monitoring disease course are shown in Table IV. The
values were significantly higher for PRL than for CEA.
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Figure 3 Patient had Dukes C grade II tumour and 14/16
metastatic pararectal lymph nodes. Post-operative chemotherapy
was given. He responded to it. He was without any complaints
for nearly 7 months. At the end of 1st year, he developed lung
metastasis. Second line chemotherapy was instituted but he did
not respond to it and finally died. PRL showed lead time and
correlated excellently with disease remission and progression.
CEA was less than 5.0 ng ml- throughout the disease course.
(--- CEA; PRL).
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Figure 4 Dukes D patient with metastasis in the liver. Pos-
toperative CEA decreased while PRL was elevated. She was given
palliative CT to which she did not respond. Both the markers
correlated well with the disease status. PRL remained elevated
whereas 100-fold increase was observed for CEA. (--- CEA;
PRL).
Discussion
The present study investigated comparison between PRL and
CEA levels with disease stage, histologic grade and disease
course in patients with colorectal adenocarcinoma. Elevated
PRL was found more often in patients with Dukes A to C
than D. Six out of ten (60%) premenopausal patients had
hyperprolactinaemia which is more frequent in our patients
with colorectal cancer. From our results we think that the
hormonal abnormalities might be responsible for the deve-
lopment and progression of the disease (Bhatavdekar et al.,
unpublished data). Dukes D patients had low level of prolac-
tin so, we have estimated PRL in the plasma and ascitic fluid
collected simultaneously in a few Dukes D patients. We
found significantly higher PRL concentrations in the ascitic
fluid compared to the circulating levels. On this basis we
presume that PRL, which is a low molecular weight polypep-
tide (approx. 23,000 dalton) easily escapes into the ascitis
from the circulation or the lymphatics (Bhatavdekar et al.,
unpublished data). However, a larger patients series is essen-
tial to confirm these preliminary results.
Plasma PRL levels correlated very well with the disease
progression. Most of these patients responded to treatment
and this was correlated with the lowering of PRL levels.
However, PRL levels increased with local/distant metastasis.
An early rise in PRL in colorectal cancer patients is an
important finding and may offer a sensitive means to predict
the presence of recurrent disease which is often difficult to
evaluate by other means. The rising PRL level is useful in
early diagnosis of progressive disease. PRL even showed a
lead time of 2-3 months. Thus, serial estimations of rising
PRL levels are useful in the early diagnosis of progressive
disease.
It was observed that though CEA levels were high in all
the Dukes stages and grades of the tumour, no intergroup
variation was observed except in Dukes D patients. Regard-
ing sequential estimations of CEA, there is some controversy
about the adequacy of CEA as a monitor of disease activity
in colorectal cancer. Some studies (Moertel et al., 1978;
Ovaska et al., 1990) have found it less sensitive and therefore
unsatisfactory whereas Staab et al. (1985) found it quite
reliable. The present study, however, suggests that CEA may
be of little practical value in local/distant metastases. Even in
patients who developed recurrence(s), CEA remained <5.0
ngml-' plasma in 24% of patients throughout the course of
the disease. In such patients, PRL accurately predicted
disease progression (Figure 3). Moreover, temporary, non-
progressive elevations of CEA were seen in 30% of patients,
which is an extreme example of this phenomenon (Rittgers et
al., 1978). Despite the lack of specificity for colon cancer,
CEA demonstrated an excellent correlation in patients with
colorectal liver metastases (Chu et al., 1982; DeBrauw et al.,
1987; Lorenz et al., 1989; Chang et al., 1989). Our study
confirms these findings with 100% score. In these patients
PRL remained high.
On the basis of the present encouraging results, we support
that CEA lacks sufficient sensitivity and specificity to detect
occult recurrence(s). CEA is most useful in monitoring
a I- . I
2-
i
-
-0- --- IGP- t-t:/A A
u
r
-980 J.M. BHATAVDEKAR et al.
patients who developed liver metastases. On the contrary,
plasma PRL is a very important independent predictor of
recurrent disease which may be due to higher sensitivity,
specificity and significantly higher predictive values.
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